| Autor: |
Jacques Mansourati, D. Mlayeh, A. Dompnier, N. Zannad, Rodrigue Garcia, H. Gorka, A. Milhem, S. Fromentin, F. Sacher, François Jourda, Walid Amara, A. Da Costa, Saida Cheggour, E. Gandjbackh, F. Georger, Jérôme Taieb |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Archives of Cardiovascular Diseases Supplements. 12:117 |
| ISSN: |
1878-6480 |
| DOI: |
10.1016/j.acvdsp.2019.09.255 |
| Popis: |
Purpose To evaluate thromboembolic complications in patients taking apixaban and undergoing a cardioversion procedure in everyday clinical practice. Methods It is a multicenter, observational, prospective study of patients with non-valvular atrial fibrillation (AF) undergoing cardioversion (electric or medical). Eligible patients had been taking apixaban (2.5 or 5 mg twice daily) for ≥ 3 weeks before the procedure, and were followed for 30 days afterwards. Results A total of 278 patients (68 [61,76] years, 71% male, mean CHA2DS2-VASc score 2, mean HAS BLED score 2) were enrolled at 25 academic/non-academic centres in France; 248 patients (89%) were receiving apixaban 10 mg/day and 29 (11%) 5 mg/day. The most prevalent concomitant disorders were hypertension (50% of patients) and diabetes (15%). The mean creatinine clearance (Cockroft − Gault) was 81 ± 34 mL/min. The majority of patients had an electric cardioversion (264, 95%)and 14 patients (5%) received amiodarone only. Cardioversion was a planned procedure in the most of cases (97%). Sixty-seven patients (24%) had a transeophageal echocardiogram before procedure. There were no reported thromboembolic events. Conclusion These observational data of patients on apixaban undergoing cardiversion in everyday practice show no thromboembolic events on a follow-up of 30 days. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect